SciClone Pharmaceuticals Company Profile (NASDAQ:SCLN)

About SciClone Pharmaceuticals (NASDAQ:SCLN)

SciClone Pharmaceuticals logoSciClone Pharmaceuticals, Inc. is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. The Company's lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets seven partnered and in-licensed products in China. The Company sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL). Its development portfolio includes Angiomax, Loramyc, Neucardin, VIBATIV and Cleviprex.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SCLN
  • CUSIP: 80862K10
  • Web: www.sciclone.com
Capitalization:
  • Market Cap: $567.1 million
  • Outstanding Shares: 51,732,000
Average Prices:
  • 50 Day Moving Avg: $10.89
  • 200 Day Moving Avg: $10.09
  • 52 Week Range: $8.55 - $11.10
P/E:
  • Trailing P/E Ratio: 15.436
  • P/E Growth: 0.820
Sales & Book Value:
  • Annual Revenue: $166.49 million
  • Price / Sales: 3.41
  • Book Value: $4.52 per share
  • Price / Book: 2.43
Profitability:
  • EBIDTA: $39.03 million
  • Net Margins: 22.50%
  • Return on Equity: 20.45%
  • Return on Assets: 18.44%
Debt:
  • Current Ratio: 10.35%
  • Quick Ratio: 9.59%
Misc:
  • Average Volume: 679,640 shs.
  • Beta: 1.71
  • Short Ratio: 0.89
 
Frequently Asked Questions for SciClone Pharmaceuticals (NASDAQ:SCLN)

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

How were SciClone Pharmaceuticals' earnings last quarter?

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) released its quarterly earnings data on Tuesday, May, 10th. The company reported $0.19 earnings per share (EPS) for the quarter. The company had revenue of $36.50 million for the quarter, compared to analyst estimates of $33.60 million. SciClone Pharmaceuticals had a return on equity of 20.45% and a net margin of 22.50%. View SciClone Pharmaceuticals' Earnings History.

Where is SciClone Pharmaceuticals' stock going? Where will SciClone Pharmaceuticals' stock price be in 2017?

1 analysts have issued 1-year price targets for SciClone Pharmaceuticals' stock. Their predictions range from $14.00 to $14.00. On average, they anticipate SciClone Pharmaceuticals' share price to reach $14.00 in the next twelve months. View Analyst Ratings for SciClone Pharmaceuticals.

Are investors shorting SciClone Pharmaceuticals?

SciClone Pharmaceuticals saw a drop in short interest in June. As of June 15th, there was short interest totalling 846,255 shares, a drop of 46.0% from the May 31st total of 1,567,831 shares. Based on an average trading volume of 1,493,546 shares, the short-interest ratio is currently 0.6 days. Currently, 1.8% of the company's stock are sold short.

Who are some of SciClone Pharmaceuticals' key competitors?

Who are SciClone Pharmaceuticals' key executives?

SciClone Pharmaceuticals' management team includes the folowing people:

  • Jon S Saxe, Independent Chairman of the Board
  • Friedhelm Blobel Ph.D., President, Chief Executive Officer, Director
  • Wilson W. Cheung, Chief Financial Officer, Senior Vice President - Finance, Secretary
  • Hong Zhao, Chief Executive Officer - China Operations
  • Raymond Anthony Low CPA, Vice President - Finance, Controller
  • Lan Xie CPA, Vice President - Finance, China Chief Financial Officer
  • Nancy T. Chang Ph.D., Independent Director
  • Richard James Hawkins, Independent Director
  • Anthony Gregg Lapointe, Independent Director
  • Simon Li, Independent Director

Who owns SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include GL PARTNERS CAPITAL MANAGEMENT LTD (9.20%), Acadian Asset Management LLC (3.39%), Fisher Asset Management LLC (0.44%), Russell Investments Group Ltd. (0.28%), Municipal Employees Retirement System of Michigan (0.17%) and Eqis Capital Management Inc. (0.09%). Company insiders that own SciClone Pharmaceuticals stock include Friedhelm Blobel, Lan Xie, Nancy T Chang and Wilson Wai-Shun Cheung. View Institutional Ownership Trends for SciClone Pharmaceuticals.

Who sold SciClone Pharmaceuticals stock? Who is selling SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Sapphire Star Partners LP, Capstone Asset Management Co. and LS Investment Advisors LLC. Company insiders that have sold SciClone Pharmaceuticals stock in the last year include Friedhelm Blobel, Lan Xie, Nancy T Chang and Wilson Wai-Shun Cheung. View Insider Buying and Selling for SciClone Pharmaceuticals.

Who bought SciClone Pharmaceuticals stock? Who is buying SciClone Pharmaceuticals stock?

SciClone Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Fisher Asset Management LLC, Eqis Capital Management Inc., Aperio Group LLC, State of Alaska Department of Revenue and Louisiana State Employees Retirement System. View Insider Buying and Selling for SciClone Pharmaceuticals.

How do I buy SciClone Pharmaceuticals stock?

Shares of SciClone Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is SciClone Pharmaceuticals' stock price today?

One share of SciClone Pharmaceuticals stock can currently be purchased for approximately $10.98.


MarketBeat Community Rating for SciClone Pharmaceuticals (NASDAQ SCLN)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  36 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about SciClone Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for SciClone Pharmaceuticals (NASDAQ:SCLN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $14.00 (27.56% upside)

Analysts' Ratings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/8/2017Maxim GroupReiterated RatingBuy -> HoldLowView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Earnings by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Earnings History by Quarter for SciClone Pharmaceuticals (NASDAQ SCLN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2017Q4 2016$0.15$0.12$44.06 millionViewListenView Earnings Details
5/10/2016Q116$0.19$33.60 million$36.50 millionViewListenView Earnings Details
3/10/2016Q415$0.30$41.10 million$42.90 millionViewListenView Earnings Details
11/9/2015Q315$0.12$0.26$40.61 million$42.90 millionViewN/AView Earnings Details
8/10/2015Q215$0.12$0.26$37.27 million$37.90 millionViewListenView Earnings Details
5/11/2015Q414$0.03$0.17$34.00 million$33.60 millionViewListenView Earnings Details
3/11/2015Q4$0.15$0.29$38.93 million$41.43 millionViewN/AView Earnings Details
11/10/2014Q314$0.12$0.17$34.90 million$34.30 millionViewN/AView Earnings Details
8/11/2014Q214$0.10$0.20$33.40 million$32.50 millionViewListenView Earnings Details
5/12/2014Q114$0.08$0.10$32.20 million$26.60 millionViewListenView Earnings Details
3/12/2014Q314$0.15$0.08$38.30 million$32.70 millionViewListenView Earnings Details
11/12/2013Q114$0.15$0.18$39.70 million$35.20 millionViewListenView Earnings Details
8/7/2013Q2 2013$0.11$0.09$33.30 million$29.81 millionViewListenView Earnings Details
4/1/2013Q4 2012$0.12$0.04$35.30 million$33.10 millionViewListenView Earnings Details
11/9/2012Q312$0.21$0.20$43.09 million$40.70 millionViewN/AView Earnings Details
8/8/2012$0.18$0.20ViewN/AView Earnings Details
5/9/2012$0.11$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for SciClone Pharmaceuticals (NASDAQ:SCLN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for SciClone Pharmaceuticals (NASDAQ:SCLN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Ownership Percentage: 5.16%
Institutional Ownership Percentage: 72.00%
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Insider Trades by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2017Friedhelm BlobelCEOSell35,044$11.00$385,484.00View SEC Filing  
6/20/2017Friedhelm BlobelCEOSell70,000$10.91$763,700.00View SEC Filing  
6/12/2017Wilson Wai-Shun CheungCFOSell40,500$10.75$435,375.00View SEC Filing  
6/8/2017Friedhelm BlobelCEOSell39,656$10.52$417,181.12View SEC Filing  
6/6/2017Friedhelm BlobelCEOSell10,300$10.00$103,000.00View SEC Filing  
5/24/2017Friedhelm BlobelCEOSell21,464$9.32$200,044.48View SEC Filing  
5/22/2017Friedhelm BlobelCEOSell18,536$9.44$174,979.84View SEC Filing  
5/11/2017Friedhelm BlobelCEOSell18,226$10.00$182,260.00View SEC Filing  
4/28/2017Friedhelm BlobelCEOSell4,400$10.01$44,044.00View SEC Filing  
4/24/2017Friedhelm BlobelCEOSell40,000$9.56$382,400.00View SEC Filing  
3/22/2017Friedhelm BlobelCEOSell40,000$9.47$378,800.00View SEC Filing  
3/16/2017Lan XieVPSell1,000$9.60$9,600.00View SEC Filing  
3/6/2017Friedhelm BlobelCEOSell3,087$10.30$31,796.10View SEC Filing  
3/3/2017Friedhelm BlobelCEOSell26,913$10.01$269,399.13View SEC Filing  
2/24/2017Friedhelm BlobelCEOSell823$9.71$7,991.33View SEC Filing  
2/23/2017Friedhelm BlobelCEOSell39,177$9.83$385,109.91View SEC Filing  
1/25/2017Friedhelm BlobelCEOSell8,868$10.54$93,468.72View SEC Filing  
1/24/2017Friedhelm BlobelCEOSell61,132$10.44$638,218.08View SEC Filing  
1/5/2017Friedhelm BlobelCEOSell9,600$11.02$105,792.00View SEC Filing  
12/22/2016Friedhelm BlobelCEOSell70,000$10.55$738,500.00View SEC Filing  
11/22/2016Friedhelm BlobelCEOSell70,000$10.22$715,400.00View SEC Filing  
11/14/2016Friedhelm BlobelCEOSell30,000$10.27$308,100.00View SEC Filing  
10/27/2016Friedhelm BlobelCEOSell40,000$9.30$372,000.00View SEC Filing  
10/26/2016Wilson Wai-Shun CheungCFOSell149,962$10.00$1,499,620.00View SEC Filing  
10/17/2016Wilson Wai-Shun CheungCFOSell1,475$10.00$14,750.00View SEC Filing  
8/30/2016Nancy T ChangDirectorSell25,040$10.30$257,912.00View SEC Filing  
8/29/2016Wilson Wai-Shun CheungCFOSell1,872$10.35$19,375.20View SEC Filing  
8/17/2016Friedhelm BlobelCEOSell501,875$10.00$5,018,750.00View SEC Filing  
8/16/2016Wilson Wai-Shun CheungCFOSell7,802$10.62$82,857.24View SEC Filing  
3/28/2016Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
3/18/2016Friedhelm BlobelCEOSell10,000$9.09$90,900.00View SEC Filing  
3/7/2016Friedhelm BlobelCEOSell20,000$10.01$200,200.00View SEC Filing  
2/26/2016Friedhelm BlobelCEOSell10,000$9.98$99,800.00View SEC Filing  
1/4/2016Friedhelm BlobelCEOSell200$9.01$1,802.00View SEC Filing  
12/28/2015Friedhelm BlobelCEOSell10,000$9.17$91,700.00View SEC Filing  
12/17/2015Friedhelm BlobelCEOSell9,400$9.00$84,600.00View SEC Filing  
12/11/2015Friedhelm BlobelCEOSell600$9.00$5,400.00View SEC Filing  
12/4/2015Friedhelm BlobelCEOSell10,000$9.22$92,200.00View SEC Filing  
12/3/2015Lan XieCFOSell14,166$9.50$134,577.00View SEC Filing  
11/27/2015Friedhelm BlobelCEOSell10,000$9.24$92,400.00View SEC Filing  
11/10/2015Wilson Wai-Shun CheungCFOSell7,803$9.51$74,206.53View SEC Filing  
7/24/2015Friedhelm BlobelCEOSell10,000$9.68$96,800.00View SEC Filing  
7/17/2015Friedhelm BlobelCEOSell10,000$9.72$97,200.00View SEC Filing  
7/10/2015Friedhelm BlobelCEOSell10,000$9.21$92,100.00View SEC Filing  
7/6/2015Friedhelm BlobelCEOSell20,000$10.80$216,000.00View SEC Filing  
6/26/2015Friedhelm BlobelCEOSell10,000$9.29$92,900.00View SEC Filing  
6/19/2015Friedhelm BlobelCEOSell10,000$9.42$94,200.00View SEC Filing  
6/12/2015Chuncai MengVPSell3,007$9.23$27,754.61View SEC Filing  
6/12/2015Friedhelm BlobelCEOSell10,000$9.13$91,300.00View SEC Filing  
6/8/2015Hong ZhaoCEOSell10,000$9.23$92,300.00View SEC Filing  
6/5/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
6/1/2015Richard J HawkinsDirectorSell4,570$9.27$42,363.90View SEC Filing  
5/29/2015Friedhelm BlobelCEOSell10,000$9.38$93,800.00View SEC Filing  
5/29/2015Richard J HawkinsDirectorSell10,430$9.32$97,207.60View SEC Filing  
5/26/2015Richard J HawkinsDirectorSell11,982$9.44$113,110.08View SEC Filing  
5/22/2015Friedhelm BlobelCEOSell10,000$9.40$94,000.00View SEC Filing  
5/18/2015Chuncai MengVPSell23,660$9.56$226,189.60View SEC Filing  
5/15/2015Lan XieCFOSell26,668$9.20$245,345.60View SEC Filing  
4/24/2015Friedhelm BlobelCEOSell10,000$9.07$90,700.00View SEC Filing  
4/10/2015Friedhelm BlobelCEOSell10,000$9.10$91,000.00View SEC Filing  
3/12/2015Wilson Wai-Shun CheungCFOSell7,803$9.07$70,773.21View SEC Filing  
12/11/2014Richard J HawkinsDirectorSell15,591$8.80$137,200.80View SEC Filing  
9/2/2014Lan XieCFOSell36,468$6.97$254,181.96View SEC Filing  
8/15/2014Nancy T ChangDirectorBuy25,040$6.00$150,240.00View SEC Filing  
5/16/2014Hong ZhaoCEOSell12,500$4.75$59,375.00View SEC Filing  
8/22/2013Min YinVPSell10,938$5.50$60,159.00View SEC Filing  
8/20/2013Min YinVPSell12,500$5.50$68,750.00View SEC Filing  
2/28/2013Friedhelm BlobelCEOBuy3,000$3.86$11,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for SciClone Pharmaceuticals (NASDAQ:SCLN)
Latest Headlines for SciClone Pharmaceuticals (NASDAQ:SCLN)
Source:
DateHeadline
americanbankingnews.com logoInsider Selling: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) CEO Sells 35,044 Shares of Stock
www.americanbankingnews.com - July 3 at 4:35 PM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) Sees Large Decrease in Short Interest
www.americanbankingnews.com - July 1 at 7:06 AM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Friedhelm Blobel Sells 70,000 Shares
www.americanbankingnews.com - June 22 at 7:28 PM
businesswire.com logoINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional ...
www.businesswire.com - June 20 at 6:37 AM
finance.yahoo.com logoSCICLONE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of SciClone Pharmaceuticals, Inc.
finance.yahoo.com - June 20 at 6:37 AM
finance.yahoo.com logoINVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - June 20 at 6:37 AM
finance.yahoo.com logoETFs with exposure to SciClone Pharmaceuticals, Inc. : June 19, 2017
finance.yahoo.com - June 20 at 6:37 AM
finance.yahoo.com logoSciClone Pharmaceuticals, Inc. :SCLN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 4:02 PM
reuters.com logoSciClone Pharmaceuticals Inc (SCLN.OQ)
www.reuters.com - June 16 at 2:08 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of SciClone Pharmaceuticals Inc. to a Consortium is Fair to Shareholders
finance.yahoo.com - June 15 at 9:05 PM
americanbankingnews.com logoInsider Selling: SciClone Pharmaceuticals, Inc. (SCLN) CFO Sells 40,500 Shares of Stock
www.americanbankingnews.com - June 14 at 10:30 PM
bizjournals.com logoWeissLaw LLP: The Proposed Acquisition of SciClone Pharmaceuticals Inc. May Not Be In the Best Interest of SCLN Shareholders
www.bizjournals.com - June 14 at 12:47 AM
finance.yahoo.com logoSCICLONE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
finance.yahoo.com - June 13 at 7:47 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of SciClone Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
finance.yahoo.com - June 13 at 7:47 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of SciClone Pharmaceuticals Inc. to a Consortium is Fair to Shareholders – SCLN
finance.yahoo.com - June 13 at 10:45 AM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Sells $417,181.12 in Stock
www.americanbankingnews.com - June 9 at 7:52 PM
baystreet.ca logoSciClone to be Bought by China-Based Group
www.baystreet.ca - June 8 at 9:53 PM
nasdaq.com logoSciClone Announces Merger; Consortium To Acquire SciClone For $11.18/shr
www.nasdaq.com - June 8 at 9:53 PM
streetinsider.com logoSciclone Pharma (SCLN) Agrees to be Acquired by Consortium Led By GL Capital for $11.18/Share
www.streetinsider.com - June 8 at 9:53 PM
finance.yahoo.com logoSciClone Enters Into Definitive Merger Agreement To Be Acquired By Consortium Led By GL Capital
finance.yahoo.com - June 8 at 9:53 PM
finance.yahoo.com logoIs SciClone Pharma Getting Enough in the Buyout?
finance.yahoo.com - June 8 at 9:53 PM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) Rating Reiterated by Maxim Group
www.americanbankingnews.com - June 8 at 2:16 PM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Sells $103,000.00 in Stock
www.americanbankingnews.com - June 6 at 8:17 PM
finance.yahoo.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : June 2, 2017
finance.yahoo.com - June 3 at 12:01 AM
americanbankingnews.com logoFriedhelm Blobel Sells 21,464 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock
www.americanbankingnews.com - May 25 at 8:05 PM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Friedhelm Blobel Sells 18,536 Shares
www.americanbankingnews.com - May 23 at 10:37 PM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Sells $182,260.00 in Stock
www.americanbankingnews.com - May 15 at 7:50 PM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) Given a $14.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 13 at 11:56 PM
finance.yahoo.com logoEdited Transcript of SCLN earnings conference call or presentation 10-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 8:02 AM
finance.yahoo.com logoSciClone Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 7:57 PM
finance.yahoo.com logoSciClone posts 1Q profit
finance.yahoo.com - May 10 at 7:57 PM
finance.yahoo.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : May 10, 2017
finance.yahoo.com - May 10 at 11:01 AM
finance.yahoo.com logoSciClone Pharmaceuticals To Report First Quarter 2017 Financial Results On May 10, 2017
finance.yahoo.com - May 4 at 9:19 AM
americanbankingnews.com logoSciClone Pharmaceuticals (SCLN) Receiving Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - May 3 at 2:14 PM
americanbankingnews.com logoSomewhat Positive News Coverage Very Likely to Impact SciClone Pharmaceuticals (SCLN) Share Price
www.americanbankingnews.com - April 30 at 5:44 PM
americanbankingnews.com logoInsider Selling: SciClone Pharmaceuticals, Inc. (SCLN) CEO Sells 4,400 Shares of Stock
www.americanbankingnews.com - April 29 at 1:30 AM
americanbankingnews.com logoSciClone Pharmaceuticals (SCLN) Given Daily News Impact Score of 0.32
www.americanbankingnews.com - April 28 at 12:40 AM
finance.yahoo.com logoSciClone Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCLN) : April 26, 2017
finance.yahoo.com - April 26 at 9:01 PM
finance.yahoo.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCLN-US : April 25, 2017
finance.yahoo.com - April 25 at 9:59 AM
americanbankingnews.com logoFriedhelm Blobel Sells 40,000 Shares of SciClone Pharmaceuticals, Inc. (SCLN) Stock
www.americanbankingnews.com - April 24 at 11:06 PM
americanbankingnews.com logoSciClone Pharmaceuticals (SCLN) Getting Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 23 at 4:47 PM
finance.yahoo.com logoSciClone Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SCLN-US : April 11, 2017
finance.yahoo.com - April 11 at 9:49 AM
benzinga.com logoSciClone To Present At Needham Healthcare...
www.benzinga.com - March 27 at 9:17 AM
finance.yahoo.com logoSciClone To Present At Needham Healthcare Conference On April 4, 2017
finance.yahoo.com - March 27 at 9:17 AM
americanbankingnews.com logoSciClone Pharmaceuticals, Inc. (SCLN) CEO Sells $378,800.00 in Stock
www.americanbankingnews.com - March 23 at 7:34 PM
finance.yahoo.com logoSCICLONE PHARMACEUTICALS INC Financials
finance.yahoo.com - March 15 at 7:58 PM
americanbankingnews.com logoInsider Selling: SciClone Pharmaceuticals, Inc. (SCLN) CEO Sells 3,087 Shares of Stock
www.americanbankingnews.com - March 8 at 11:54 PM
seekingalpha.com logoSciClone Pharmaceuticals' (SCLN) CEO Friedhelm Blobel on Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 7 at 7:35 PM
finance.yahoo.com logoEdited Transcript of SCLN earnings conference call or presentation 6-Mar-17 1:30pm GMT
finance.yahoo.com - March 7 at 9:18 AM
us.rd.yahoo.com logoSciClone Reports 2016 Financial Results And 2017 Outlook
us.rd.yahoo.com - March 6 at 11:38 AM

Social

Chart

SciClone Pharmaceuticals (SCLN) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff